Deadline for Abstract Submission:
19 September 2022
Deadline for Early-Bird Registration:
19 October 2022


Dr. Ban-Leong SNG
Senior Consultant & Head of Department at Women's Anaesthesia
KK Women's and Children's Hospital

Associate Professor Sng Ban Leong is the current Head and Senior Consultant at the Department of Women’s Anaesthesia at KK Women’s and Children’s Hospital, Singapore. He is also an Associate Professor and Academic Vice Chair (Research) in the Singhealth Duke-NUS Academic Medical Centre Anaesthesiology and Perioperative Sciences Academic Clinical Program. Ban Leong is a National Level Clinician Scientist in Singapore (with 2 clinician scientist awards, 1 transition award by National Medical Research Council) and has done clinical innovation work funded by national grants. He has more than 100 peer reviewed publications and written several book chapters. Ban Leong is also a Core Faculty in the Singhealth Anaesthesiology Residency Program and is a mentor in the Duke-NUS Medical School research year curriculum. His research interest is in obstetric anaesthesia and analgesia, childbirth pain and psychological vulnerability, novel drug delivery and feedback systems.

Remifentanil for Labour Analgesia

Intravenous remifentanil patient controlled analgesia (PCA) is an alternative option for labour pain relief. The gold standard of labour analgesia is the administration of epidural analgesia and other options may include intramuscular pethidine and Entonox administration. The pharmacokinetics nature of remifentanil enables the drug to be administered using the PCA route, but even with patient feedback there has been case reports of adverse events. There has been concerns on the efficacy and safety of this analgesic option and its role in the delivery suite. Given the potential opioid induced respiratory depression and sedation risk, the provision of remifentanil PCA service is labour intensive and vital signs monitoring is required. Database network of remifentanil PCA usage from different countries will hope to provide best practices in remifentanil PCA service. This talk will also discuss the evidence for remifentanil PCA, its efficacy and safety, recent innovations to improve patient safety and guidelines to consider during remifentanil PCA administration.